Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple centers, prospective, phase II trial of gemcitabine and docetaxel combination chemotherapy in patients with locally advanced/metastatic soft tissue sarcoma or imatinib mesylate refractory advanced/metastatic malignant gastrointestinal stromal tumor

X
Trial Profile

Multiple centers, prospective, phase II trial of gemcitabine and docetaxel combination chemotherapy in patients with locally advanced/metastatic soft tissue sarcoma or imatinib mesylate refractory advanced/metastatic malignant gastrointestinal stromal tumor

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Gastrointestinal stromal tumours; Soft tissue sarcoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jul 2009 Planned end date changed from 1 Apr 2007 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 08 Nov 2006 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top